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Extant evidence implicates growth factor signaling in the pathogenesis of many tumor types, including cutaneous
melanoma. Recently, reciprocal activating mutations of NRAS and BRAF were found in benign melanocytic nevi
and cutaneous melanomas. We had previously reported a similar epistatic relationship between activating NRAS
mutations and inactivating PTEN/MMAC1 alterations. We thus hypothesized that BRAF and PTEN/MMAC1
mutations may cooperate to promote melanoma tumorigenesis. Overall, 40 of 47 (85%) melanoma cell lines and 11
of 16 (69%) uncultured melanoma metastases had mutations in NRAS, BRAF, or PTEN/MMAC1. NRAS was
exclusively mutated in nine of 47 (19%) cell lines and two of 16 (13%) metastases, whereas BRAF was solely
mutated in 28 of 47 (60%) cell lines and nine of 16 (56%) metastases. In the 12 of 15 melanoma cell lines (80%) and
two of two melanoma metastases with PTEN alterations, BRAF was also mutated. These ﬁndings suggest the
existence of possible cooperation between BRAF activation and PTEN loss in melanoma development.
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Sustained growth factor signaling is a critical step in the
evolution of cutaneous melanoma. In vitro, basic fibroblast
growth factor can form an autocrine stimulatory loop (Meier
et al, 2000; Graeven et al, 2001), whereas in vivo, transgenic
expression of the receptor tyrosine kinase, RET (Iwamoto
et al, 1991; Kato et al, 1998), leads to melanocytic tumors.
Post-receptor, activating RAS mutations have also been
reported in a significant proportion of cutaneous melano-
mas (Herlyn and Satyamoorthy, 1996; van Elsas et al, 1996).
Two distinct RAS signaling streams—the RAS/RAF/MAPK
and the RAS/PI3-K/PTEN/AKT pathways—have both been
shown to be activated in primary melanomas (Cohen et al,
2002; Dhawan et al, 2002; Govindarajan et al, 2003;
Satyamoorthy et al, 2003). Moreover, BRAF, which is a
component of the RAS/RAF/MAPK signaling cassette, was
recently found to be mutated in 60% to 80% of cutaneous
melanomas and benign melanocytic nevi (Davies et al,
2002; Pollock et al, 2003). Taken together, the RAS signaling
network represents a rich source of oncogenic events.
We had previously demonstrated a reciprocal relationship
between NRAS activation and PTEN/MMAC1 inactivation in
melanoma cell lines and uncultured specimens (Tsao et al,
2000). As RAS directly stimulates PI3-K (Rodriguez-Viciana
et al, 1996, 1997) and PTEN attenuates PI3-K signaling
(Maehama and Dixon, 1998; Wu et al, 1998), reciprocal
NRAS and PTEN/MMAC1 alterations may contribute to the
heightened AKT activity observed in melanomas (Dhawan et
al, 2002). As loss of PTEN protein expression occurs in 63%
of primary melanomas and only 8% of nevi (Tsao et al, 2003),
inactivation of PTEN/MMAC1 may be a feature of progres-
sion from melanocytic nevi to primary melanoma.
Likewise, a similar epistatic relationship between onco-
genic alleles of NRAS and BRAF has also been described
(Davies et al, 2002; Pollock et al, 2003). As RAS activates
RAF leading to MAPK stimulation (Campbell et al, 1998),
reciprocal NRAS and BRAF mutations may account for the
increased MAPK activity reported for melanoma (Cohen
et al, 2002; Govindarajan et al, 2003; Satyamoorthy et al,
2003). The genetic relationship described for NRAS, BRAF,
and PTEN/MMAC1 raises the possibility that BRAF activa-
tion and PTEN/MMAC1 inactivation cooperate to simulate
NRAS activation in order to promote melanoma tumorigen-
esis. To test this hypothesis directly, we screened for BRAF
mutations in a series of melanoma samples whose NRAS
and PTEN/MMAC1 had been previously characterized and
found evidence for possible cooperation between BRAF
and PTEN/MMAC1.
Results and Discussion
Using PCR–single strand conformation polymorphism, we
evaluated 47 melanoma cell lines and 16 uncultured
metastatic melanoma specimens for mutations in exons
11 and 15 of BRAF. Whereas no exon 11 amplicons
exhibited altered migration, multiple exon 15 amplicons
demonstrated mobility shifts suggestive of sequence
variants (Fig 1a). After direct sequencing, we found that 28
of 47 (62%) melanoma lines harbored mutations at va-
line599– 26 lines had the canonical T1796A (BRAFV599E)
mutation, whereas two lines harbored the TG1796-97AT1These authors contributed equally to the work.
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(BRAFV599D) mutation. The BRAFV599E mutation was also
present in nine of 16 (56%) uncultured metastatic melano-
ma specimens.
In three of 28 melanoma cell lines with BRAFV599
mutations, the normal BRAF allele was deleted (Fig 1a,b).
Although loss of heterozygosity is typically a signature of a
tumor suppressor locus, shedding of the wild-type allele
has been described for NRAS (Osaka et al, 1997), KRAS
(Sukumar et al, 1991), and HRAS (Saranath et al, 1991). As
the BRAFV599 alterations are presumably gain-of-function
mutations, the normal allele would represent a hypo-
functional competitor whose loss could potentiate the effec-
tiveness of the BRAFV599 variant. Alternatively, Diaz et al
(2002), recently found that the presence of a wild-type NRAS
allele impedes the formation of murine lymphomas in vivo
and suppresses the malignant phenotype in vitro; thus, it is
conceivable that the BRAF proto-oncogene may exhibit
tumor suppressive properties under certain biologic contexts.
The NRAS, BRAF, and PTEN/MMAC1 status for the
various cell lines and specimens are shown in Tables I and
II. Overall, 40 of 47 (85%) melanoma cell lines and 11 of 16
(69%) uncultured melanoma metastases had mutations in
at least one of the three loci. Several observations emerged
from our analysis. First, NRAS was solely mutated in nine
melanoma cell lines and two uncultured melanoma speci-
mens, although there was one additional cell line that
exhibited concurrent NRAS and PTEN/MMAC1 alterations
(i.e., HS944; Tsao et al, 2000). Second, 15 cell lines and two
uncultured metastases exhibited either PTEN/MMAC1
mutations (11 lines, both metastases) or loss of protein
expression (four lines, Table I); epigenetic silencing of PTEN/
MMAC1 has been reported in cutaneous melanoma (Zhou
et al, 2000). Of the 63 samples analyzed, BRAF was
mutated in 12 of 15 (80%) and two of two (100%) of the
PTEN-deficient lines and metastatic specimens, respec-
tively (p¼ 0.02, two-tailed Fisher exact test). An additional
16 melanoma lines and seven uncultured metastases
displayed BRAF mutations without either NRAS or PTEN/
MMAC1 participation. Finally, two melanoma lines showed
PTEN/MMAC1 inactivation without BRAF involvement.
We report, for the first time that, in a subset of
melanomas, BRAF activation accompanies PTEN/MMAC1
inactivation to the mutual exclusion of NRAS mutations.
These results suggest that (1) BRAF and PTEN/MMAC1
operate on distinct genetic pathways and could cooperate
to promote melanoma tumorigenesis, and (2) a single NRAS
mutation, albeit not as common as alterations in either
BRAF or PTEN/MMAC1, may be sufficient (model shown in
Fig 2). As BRAF and PTEN selectively impact the MAPK and
AKT pathways, respectively, activation of both signaling
streams may be required for melanoma progression.
Cohen et al (2002), found that over 80% of primary
cutaneous melanomas, but only 20% of benign nevi,
expressed active phosphoMAPK. Satyamoorthy et al
(2003), also reported that vertical growth phase and
metastatic melanomas, but not benign nevi, stained
intensely for active phosphoERK and that the ERK
phosphorylation in melanoma cell lines was abrogated by
the MEK inhibitor PD98059. With respect to the AKT
pathway, Dhawan et al (2002), found increased staining for
active phosphoAKT in metastatic melanoma specimens but
not benign nevi and observed loss of AKT phosphorylation
in melanoma cell lines exposed to PI3-K inhibitors,
LY294002 and wortmannin. These data, along with our
findings, point to an essential role for ongoing trophic
signaling, through both MAPK and AKT pathways.
The high rate of BRAF mutations in nevi (Pollock et al,
2003; Uribe et al, 2003) implies that the MAPK pathway is
genetically engaged early in melanocytic tumor formation
but is insufficient to induce full malignant transformation;
other events are clearly necessary for progression. We
recently found that 19 of 30 (63%) primary melanomas
demonstrated significant decreases in PTEN levels,
although only three of 39 melanocytic nevi (8%) exhibited
loss of PTEN expression (Tsao et al, 2003); these results
parallel other observations that active phosphoAKT can be
detected in melanomas but not in melanocytic nevi
(Dhawan et al, 2002). Thus, unlike BRAF activation, PTEN
loss appears to be more specific for melanoma tumorigen-
esis. Taken together, one hypothesis that emerges is that
loss of PTEN cooperates with activation of BRAF in the
transition from nevus to melanoma.
The high BRAF mutation rate, especially in melanoma,
raises the possibility of an effective anti-BRAF therapy. As
Figure 1
(A) PCR–single strand conformation poly-
morphism. Analysis of BRAF exon 15.
Amplified exon 15 fragments containing the
normal (V599) and mutant (E599) variants
exhibit differential mobilities, as indicated by
the upper and lower arrows, respectively. The
asterisk marks the presence of the mutant
allele. Note that the cell line in lane 3 is
homozygous for the E599 mutation (lane 1:
Mel-Swift; lane 2: MGH-BO-1; lane 3: SK-Mel
28; lane 4: WM455; lane 5: SK-Mel 63). (B)
BRAF genotypes showing loss of normal
allele at codon 599.
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Table I. BRAF, NRAS, and PTEN/MMAC1 mutations in melanoma cell lines
Cell line
NRASa PTEN/MMAC1 BRAF exon 15
Mutation Effect Mutation Effect Mutation Effect
MGH-MC-2 G35A G12D wt WT wt WT
Mel-Swift C180A Q61K wt WT wt WT
MGH-PO-1 C180A Q61K wt WT wt WT
SK Mel-l19 A181G Q61R wt WT wt WT
SK Mel-30 C180A Q61K wt WT wt WT
Mel Juso A181T Q61L wt WT wt WT
K19 C180A Q61K wt WT wt WT
HS940 A181G Q61R wt WT wt WT
SK Mel 63 C180A Q61K wt WT wt WT
HS944 C180A Q61K Del exon2 Frameshift/premature stop wt WT
SK Mel 39 wt WT 546insA Frameshift/premature stop T1796A V599E
MGH-BO-1 wt WT Del exon2 Frameshift/premature stop T1796A V599E
Sk Mel37 wt WT Del exon 2 Frameshift/premature stop T1796A V599E
UACC 903 wt WT T226G Tyr 76 Stop T1796A V599E
RU wt WT IVS3delþ1 ! þ4 Possible splice variant T1796A V599E
MM455 wt WT Del exon 6 Frameshift/premature stop T1796A V599E
SK Mel 28 wt WT A499G T167A T1796Ab 599E
SK Mel 131 wt WT IVS5þ2T ! A Possible splice variant T1796A V599E
MEL-11 wt WT wt No proteinc T1796A V599E
WM1158 wt WT wt No proteinc T1796A V599E
WM239A wt WT wt No proteinc TG1796–97AT V599D
WM1799 wt WT Failed PCR No proteinc T1796A V599E
SK Mel 23 wt WT Del gene No predicted product wt WT
ML wt WT Del gene No predicted product wt WT
MGH-MC-1 wt WT wt WT T1796A V599E
K1-Mel wt WT wt WT T1796A V599E
MEL-31 wt WT wt WT T1796A V599E
WM164 wt WT wt WT T1796A V599E
MH-12 wt WT wt WT TG1796–97AT V599D
MH-2 wt WT wt WT T1796A V599E
K-16 wt WT wt WT T1796A V599E
A375 wt WT wt WT T1796Ab 599E
HS939T wt WT wt WT T1796A V599E
MH-17 wt WT wt WT T1796A V599E
Malme wt WT wt WT T1796A V599E
K4 wt WT wt WT T1796A V599E
Steele wt WT wt WT T1796A V599E
K2 wt WT wt WT T1796A V599E
WM115 wt WT wt WT T1796A V599E
MM608 wt WT wt WT T1796Ab 599E
aNRAS, PTEN/MMAC1 status on some cell lines published in Tsao et al (2000).
bBoth alleles show 599E.
cNo protein by western.
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our data document a significant rate of concurrent muta-
tions in the RAS/PI3-VK/PTEN/AKT pathway, monotherapy
targeted at BRAF alone may be ineffectual. Further studies
will obviously be necessary in order to optimize rationale
drug design.
In summary, we have identified a potential genetic
interaction between three components of the RAS signaling
network—NRAS, BRAF, and PTEN/MMAC1. Based on the
known cellular functions of these respective gene products,
the pattern of mutations suggest that the MAPK and AKT
pathways are frequently activated in parallel, by genetic
means, to promote melanoma development.
Materials and Methods
Cell lines and DNA The human melanoma cell lines, culture
conditions, uncultured melanoma specimens, and their NRAS and
PTEN/MMAC1 status have been described previously (Tsao et al,
2000). All studies were done in accordance with a protocol
approved by the IRB at the Massachusetts General Hospital.
Polymerase chain reaction (PCR)–single strand conformation
polymorphism Primer sequences for the exons 11 and 15 of
BRAF are published (Davies et al, 2002). Amplification was carried
out in 50 mL reaction containing 1 mL of DNA, 1.5 mM MgCl2 and 40
ng of each primer under standard conditions with or without 0.25
mL of [a32P]deoxycytidine triphosphate (NEN, Boston, Massachu-
setts). The samples were initially denatured at 951C 5 min, than
amplified for 35 cycles of 951C 1 min, 621C 1.5 min, 721C 1.5 min,
and final extension at 721C for 10 min. The PCR product was
confirmed on 1.2% agarose gel. Ten microliters of PCR product
was then mixed with 10 mL of the gel loading buffer (95%
formamide, 10 mM EDTA, 0.02% bromophenol blue and 0.02%
xylene cyanol FF) and the samples were denatured at 951C for
5 min and chilled immediately for 5 min. The sample was loaded on
to 6% acrylamide gel containing 10% glycerol, 1  TBE pH 8.0.
The gel was run in 0.6  TBE at 5–6 W at 41C for 5 to 6 h. The gel
was either stained with a silver staining kit (DNA Silver Staining Kit,
Amersham/Pharmacia, Uppsala, Sweden) or exposed to X-ray film
(Biomax-MR, Kodak, Rochester, New York), if radioactivity was
used. DNA fragments showing mobility shifts were than prepared
by PCR under the same condition, purified using Qiaquick PCR
purification kit per manufacturer’s protocol (Qiagen Inc., Valencia,
California) and submitted to Massachusetts General Hospital
sequencing core facility for automated sequencing.
Western blotting Whole cell lysate was prepared from the
melanoma cell lines using RIPA buffer (150 mM NaCl, 50 mM Tris
pH 8.0, 1% nonidet P40, 0.1% sodium dodecyl sulfate, 0.5%
sodium deoxycholate, 5 mg per mL each of aprotinin and leupeptin
and 1 mM of phenylmethylsulfonyl fluoride) containing the cocktail
of protease inhibitors (Roche Molecular Biology). Fifty micrograms
of protein were loaded on to sodium dodecyl sulfate–polyacryla-
mide gel electrophoresis gel and transferred on to nitrocellulose
paper. The blot was incubated with an anti-PTEN monoclonal
antibody at 1:1000 (A2B1, Santa Cruz Biotechnology Inc., Santa
Cruz, California). After washing, incubating with secondary anti-
body (sheep anti-mouse horseradish peroxidase; Amersham
Table II. BRAF, NRAS, and PTEN/MMAC1 mutationsa in melanoma metastases
Cutaneous melanoma specimens
NRAS PTEN/MMAC1 BRAF Exon 15
Mutation Effect Mutation Effect Mutation Effect
30 A181G Q61R wt WT wt WT
7 A181G Q61R wt WT wt WT
31 (KM16) wt WT ROH HD T1796A V599E
33 (KM17) wt WT 1591 Dup Frameshift T1796A V599E
(nt1575–1591) 271 stop
6 wt WT wt WT T1796A V599E
8 wt WT wt WT T1796A V599E
16 wt WT wt WT T1796A V599E
22 wt WT wt WT T1796A V599E
24 wt WT wt WT T1796A V599E
25 wt WT wt WT T1796A V599E
28 wt WT wt WT T1796A V599E
4 wt WT wt WT wt WT
15 wt WT wt WT wt WT
12 wt WT wt WT wt WT
9 wt WT wt WT wt WT
10 wt WT wt WT wt WT
aPTEN/MMAC1 and NRAS genetic status reported in Tsao et al (1998, 2000). ROH: retention of heterozygosity.
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Biosciences, Piscataway, New Jersey), the blot was developed
with chemiluminescent substrate.
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Figure 2
Model of various genetic interactions. (A) Normal NRAS stimulates
BRAF and PI3-K thereby activating downstream effectors MAPK and
AKT, respectively. (B) An NRAS mutation activates both pathways. (C)
Activation of BRAF accompanied by concurrent loss of PTEN
cooperate to trigger signaling in both pathways. (D) An isolated BRAF
mutation unaccompanied by PTEN loss may still engage the AKT
signaling through unknown mechanisms.
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